Xiamen University

Xiamen Innovax Biotech Co., Ltd.

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.

Huirong Pan

Ningshao Xia

Jun Zhang

Shaowei Li

Shengxiang Ge

Minxi Wei

Bo Liu

Tingdong Li

Ji Miao

Yijian Li

Lianzhi Jia

Miaoge Xue

Yuanjun Zeng

Xianglin Kong

Minghui Xie

Xiaobing Mo

Wentong Shen

Zhongyi Li

The invention relates to a truncated rotavirus VP4 protein, a sequence encoding the same, a method for preparing the same, and a pharmaceutical composition and a vaccine comprising the protein, wherein the protein, the pharmaceutical composition and the vaccine are useful for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea. The invention further relates to use of the protein in the manufacture of a pharmaceutical composition or a vaccine for preventing, alleviating or treating rotavirus infection and a disease caused by rotavirus infection, such as rotavirus gastroenteritis and diarrhea.

Truncated rotavirus VP4 protein and application thereof

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the truncated L1 protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

Truncated L1 protein of human papillomavirus type 6

Provided is a truncated L1 protein of Human Papillomavirus (HPV) Type 52 which, compared to a wild type HPV52 L1 protein, is truncated by 27-42 amino acids at the N-terminal. Also provided are a coding sequence of the truncated HPV52 L1 protein, a virus-like particle (VLP) comprising the protein, and a method of preparing the protein and the VLP using anexpression system. The truncated HPV52 L1 protein and an assembled VLP can be used to prevent an HPV52 infection and a disease caused by HPV52 infection, such as cervical cancer.

Truncated L1 protein of human papillomavirus type 52

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 18, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of cervical cancer.

Truncated L1 protein of human papillomavirus type 18

The present invention relates to a truncated L1 protein of Human Papillomavirus (HPV) Type 33, a sequence encoding the same, a method for preparing the same, and a virus-like particle comprising the same, wherein the protein and the virus-like particle are useful for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer. The invention also relates to the use of the protein and the virus-like particle in the preparation of a pharmaceutical composition or a vaccine for preventing HPV (particularly HPV33) infection, and a disease caused by HPV (particularly HPV33) infection, such as cervical cancer.

Truncated L1 protein of human papillomavirus type 33

The invention relates to a truncated L1 protein of the Human Papillomavirus Type 6, a virus-like particle consisting of the protein, a vaccine comprising said virus-like particle, and the use of the vaccine in the prevention of condyloma acuminatum or HPV infections.

Growing community of inventors

Xiamen, China

Huirong Pan